Astellas Pharma is actively transforming its drug development strategy by internalizing clinical operations and leveraging AI technologies to enhance efficiency.
The company, under the leadership of Tadaaki Taniguchi, is moving away from outsourcing by establishing a dedicated team to manage the entire lifecycle of each asset. This shift allows Astellas to conduct trials with its own research teams, significantly speeding up processes and improving communication across its global operations. AI plays a crucial role in this transformation, particularly in areas like protocol development and document translation, which are essential for conducting clinical trials in multiple countries.
As Astellas reduces its reliance on contract research organizations (CROs), it has reported substantial cost savings, contributing to a total of $406 million over the past two years. This internalization comes at a critical time as the company faces a patent expiration for its cancer drug Xtandi, prompting a focus on advancing its pipeline in immuno-oncology, gene therapy, and more.
Among its promising candidates is setidegrasib, a KRAS-targeting treatment currently in phase 3 trials for pancreatic cancer. Astellas aims to differentiate itself from competitors like Revolution Medicines by offering a drug that degrades the target protein rather than merely inhibiting it, potentially leading to a better safety profile. The company is also advancing other candidates, such as ASP2138 for gastric cancer and a gene therapy for Pompe disease, indicating a strategic pivot towards innovative therapies that could drive future growth.
This strategic overhaul not only positions Astellas to better navigate impending challenges but also underscores the growing importance of AI in streamlining clinical operations within the life sciences sector.